Entera Bio says Phase 2 post-hoc analysis supports anabolic effect of oral EB613 in high-risk postmenopausal osteoporosis patients

Reuters2026/08/04 12:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Entera Bio flagged new post-hoc Phase 2 analyses of EB613, an oral bone-forming osteoporosis tablet, selected for presentation at ASBMR 2026.
Results were not previously disclosed; they are scheduled for October 9-12, 2026, including a plenary poster session.
The analysis indicates stronger bone-building effects in postmenopausal women with more severe osteoporosis and higher fracture risk.
Entera plans a single Phase 3 trial in about 750 postmenopausal women to support a potential NDA filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040830PRIMZONEFULLFEED9802831) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Entera Bio says Phase 2 post-hoc analysis supports anabolic effect of oral EB613 in high-risk postmenopausal osteoporosis patients

You may also like

Crypto prices